ENVERIC BIOSCIENCES INC (ENVB) Stock Fundamental Analysis

NASDAQ:ENVB • US29405E5050

2.42 USD
+0.18 (+8.04%)
At close: Feb 19, 2026
2.055 USD
-0.36 (-15.08%)
Pre-Market: 2/20/2026, 7:21:48 AM
Fundamental Rating

2

Overall ENVB gets a fundamental rating of 2 out of 10. We evaluated ENVB against 191 industry peers in the Pharmaceuticals industry. While ENVB seems to be doing ok healthwise, there are quite some concerns on its profitability. ENVB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ENVB had negative earnings in the past year.
  • ENVB had a negative operating cash flow in the past year.
  • ENVB had negative earnings in each of the past 5 years.
  • In the past 5 years ENVB always reported negative operating cash flow.
ENVB Yearly Net Income VS EBIT VS OCF VS FCFENVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • ENVB's Return On Assets of -257.81% is on the low side compared to the rest of the industry. ENVB is outperformed by 91.62% of its industry peers.
  • With a Return On Equity value of -325.39%, ENVB is not doing good in the industry: 76.96% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -257.81%
ROE -325.39%
ROIC N/A
ROA(3y)-267.33%
ROA(5y)-230.52%
ROE(3y)-532.66%
ROE(5y)-403.62%
ROIC(3y)N/A
ROIC(5y)N/A
ENVB Yearly ROA, ROE, ROICENVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ENVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENVB Yearly Profit, Operating, Gross MarginsENVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

6

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ENVB has more shares outstanding
  • Compared to 5 years ago, ENVB has more shares outstanding
  • There is no outstanding debt for ENVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ENVB Yearly Shares OutstandingENVB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K 40K 50K
ENVB Yearly Total Debt VS Total AssetsENVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • ENVB has an Altman-Z score of -40.41. This is a bad value and indicates that ENVB is not financially healthy and even has some risk of bankruptcy.
  • ENVB has a Altman-Z score of -40.41. This is amonst the worse of the industry: ENVB underperforms 90.05% of its industry peers.
  • There is no outstanding debt for ENVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -40.41
ROIC/WACCN/A
WACCN/A
ENVB Yearly LT Debt VS Equity VS FCFENVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 4.60 indicates that ENVB has no problem at all paying its short term obligations.
  • ENVB has a Current ratio of 4.60. This is in the better half of the industry: ENVB outperforms 63.35% of its industry peers.
  • A Quick Ratio of 4.60 indicates that ENVB has no problem at all paying its short term obligations.
  • ENVB's Quick ratio of 4.60 is fine compared to the rest of the industry. ENVB outperforms 65.97% of its industry peers.
Industry RankSector Rank
Current Ratio 4.6
Quick Ratio 4.6
ENVB Yearly Current Assets VS Current LiabilitesENVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

1

3. Growth

3.1 Past

  • ENVB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.83%, which is quite impressive.
EPS 1Y (TTM)79.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ENVB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.17% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.66%
EPS Next 2Y41.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENVB Yearly Revenue VS EstimatesENVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2027 2028 2029 2030 2031 50M 100M
ENVB Yearly EPS VS EstimatesENVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2021 2022 2023 2024 2025 2026 -5K -10K -15K -20K -25K

1

4. Valuation

4.1 Price/Earnings Ratio

  • ENVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ENVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENVB Price Earnings VS Forward Price EarningsENVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENVB Per share dataENVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200 -250

4.3 Compensation for Growth

  • ENVB's earnings are expected to grow with 41.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.17%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • No dividends for ENVB!.
Industry RankSector Rank
Dividend Yield 0%

ENVERIC BIOSCIENCES INC

NASDAQ:ENVB (2/19/2026, 8:00:01 PM)

Premarket: 2.055 -0.36 (-15.08%)

2.42

+0.18 (+8.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)03-26
Inst Owners10.58%
Inst Owner Change-86.83%
Ins Owners0.45%
Ins Owner Change0%
Market Cap3.36M
Revenue(TTM)N/A
Net Income(TTM)-11.25M
Analysts82.86
Price Target122.4 (4957.85%)
Short Float %6.35%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-255.6
EYN/A
EPS(NY)-1.78
Fwd EYN/A
FCF(TTM)-5.52
FCFYN/A
OCF(TTM)-5.52
OCFYN/A
SpS0
BVpS2.49
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -257.81%
ROE -325.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-267.33%
ROA(5y)-230.52%
ROE(3y)-532.66%
ROE(5y)-403.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.6
Quick Ratio 4.6
Altman-Z -40.41
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.91%
EPS Next Y99.66%
EPS Next 2Y41.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.03%
EBIT Next 3Y2.98%
EBIT Next 5Y33.29%
FCF growth 1Y51.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.5%
OCF growth 3YN/A
OCF growth 5YN/A

ENVERIC BIOSCIENCES INC / ENVB FAQ

What is the fundamental rating for ENVB stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENVB.


Can you provide the valuation status for ENVERIC BIOSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to ENVERIC BIOSCIENCES INC (ENVB). This can be considered as Overvalued.


Can you provide the profitability details for ENVERIC BIOSCIENCES INC?

ENVERIC BIOSCIENCES INC (ENVB) has a profitability rating of 0 / 10.


What is the expected EPS growth for ENVERIC BIOSCIENCES INC (ENVB) stock?

The Earnings per Share (EPS) of ENVERIC BIOSCIENCES INC (ENVB) is expected to grow by 99.66% in the next year.